The objective of the review is to evaluate whether switching IBD patients from the originator to the biosimilar IFX is safe and effective in patients with quiescent IBD receiving maintenance therapy.
This is a protocol.
Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab
Health topics:
Gastroenterology & hepatology > Inflammatory bowel disease > Crohn's disease: induction of remission
Gastroenterology & hepatology > Inflammatory bowel disease > Crohn's disease: maintenance of remission
Share